SUPPLEMENTAL DATA

Supplemental Figure 1. Study design and experimental protocol



Legend: *Type 1 diabetes only. † RAASi withdrawal. ‡ At baseline and during ANGII

ANGII, angiotensin II; POC, point of care; PWV, pulse wave velocity; RAASi, renin-angiotensin-aldosterone system inhibitor.

Supplemental Table 1. Heart rate variability correlations in DKD resistors (A) and DKD (B) in type 1 diabetes in response to exogenous RAAS stimulation with ANGII

(A) DKD resistors

	ΔRVR in response to low dose ANG II	ΔRVR in response to high dose ANGII	ΔSBP in response to low dose ANGII	ΔSBP in response to high dose ANGII
RMSSD*	**r=0.41, p=0.009**	**r=0.36, p=0.021**	r=0.28, p=0.075	r=0.14, p=0.39
SDNN*	r=0.31, p=0.051	r=0.27, p=0.10	r=0.23, p=0.14	r=0.08, p=0.63
SDNN/RMSSD	**r=-0.40, p=0.010**	**r=-0.40, p=0.012**	r=-0.19, p=0.22	r=-0.12, p=0.46
LF/HF Ratio*	**r=-0.40, p=0.012**	**r=-0.48, p=0.002**	r=-0.07, p=0.65	r=-0.22, p=0.16

* Natural log-transformed

(B) DKD

	ΔRVR in response to low dose ANG II	ΔRVR in response to high dose ANG II	ΔSBP in response to low dose ANGII	ΔSBP in response to high dose ANG II
RMSSD*	r=0.17, p=0.50	r=-0.03, p=0.89	**r=0.47, p=0.035**	r=0.14, p=0.57
SDNN*	r=0.04, p=0.86	r=-0.25, p=0.31	r=0.29, p=0.22	r=-0.04, p=0.88
SDNN/RMSSD	r=-0.26, p=0.27	r=-0.15, p=0.55	r=-0.43, p=0.053	r=-0.24, p=0.33
LF/HF Ratio*	r=-0.29, p=0.22	r=-0.34, p=0.16	r=-0.43, p=0.060	r=-0.29, p=0.23

* Natural log-transformed

DKD, diabetic kidney disease; ANGII, angiotensin II; HF, high frequency; LF, low frequency; RMSSD, root mean square successive difference; SDNN, sympathetic activity, standard deviation of normal-to-normal interval; RVR, renal vascular resistance.